HC Wainwright Weighs in on Travere Therapeutics, Inc.’s FY2026 Earnings (NASDAQ:TVTX)

Travere Therapeutics, Inc. (NASDAQ:TVTX) – HC Wainwright lowered their FY2026 EPS estimates for shares of Travere Therapeutics in a note issued to investors on Tuesday, May 7th. HC Wainwright analyst E. Arce now forecasts that the company will post earnings per share of $0.13 for the year, down from their previous forecast of $0.20. HC Wainwright has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.10) per share.

Several other equities research analysts have also recently weighed in on the company. Wedbush restated an “outperform” rating and set a $13.00 target price on shares of Travere Therapeutics in a report on Wednesday, April 17th. Canaccord Genuity Group increased their target price on Travere Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday. Guggenheim restated a “neutral” rating on shares of Travere Therapeutics in a report on Wednesday, March 27th. Wells Fargo & Company raised their target price on Travere Therapeutics from $8.00 to $9.00 and gave the company an “equal weight” rating in a research note on Friday, February 16th. Finally, Piper Sandler lifted their price objective on Travere Therapeutics from $10.00 to $11.00 and gave the company a “neutral” rating in a research note on Thursday, January 18th. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $16.69.

Travere Therapeutics Price Performance

Shares of TVTX stock traded down $0.17 during trading on Friday, hitting $6.43. The company had a trading volume of 100,152 shares, compared to its average volume of 1,268,153. Travere Therapeutics has a 52 week low of $5.12 and a 52 week high of $19.54. The stock has a market capitalization of $489.39 million, a price-to-earnings ratio of -4.10 and a beta of 0.69. The company has a quick ratio of 3.41, a current ratio of 3.47 and a debt-to-equity ratio of 1.88. The stock’s 50-day moving average is $6.97 and its two-hundred day moving average is $7.59.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings data on Monday, May 6th. The company reported ($1.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.78). The firm had revenue of $41.40 million for the quarter, compared to analysts’ expectations of $43.46 million. Travere Therapeutics had a negative return on equity of 177.97% and a negative net margin of 56.02%. Travere Therapeutics’s revenue was up 34.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.27) earnings per share.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. ProShare Advisors LLC lifted its position in shares of Travere Therapeutics by 9.2% in the first quarter. ProShare Advisors LLC now owns 18,421 shares of the company’s stock valued at $142,000 after acquiring an additional 1,557 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Travere Therapeutics by 79.2% during the 1st quarter. Russell Investments Group Ltd. now owns 184,623 shares of the company’s stock valued at $1,423,000 after buying an additional 81,611 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of Travere Therapeutics during the 1st quarter valued at about $452,000. Oak Ridge Investments LLC increased its holdings in Travere Therapeutics by 13.3% during the 1st quarter. Oak Ridge Investments LLC now owns 65,926 shares of the company’s stock worth $508,000 after purchasing an additional 7,744 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Travere Therapeutics by 8.1% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 50,178 shares of the company’s stock worth $387,000 after purchasing an additional 3,754 shares during the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.